Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Follow-Up Questions
IMRN 주식의 가격 성능은 어떻습니까?
IMRN의 현재 가격은 $1.92이며, 전 거래일에 increased 1.1% 하였습니다.
Immuron Ltd의 주요 사업 주제나 업종은 무엇입니까?
Immuron Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
